Abstract
Objective
Previous studies have demonstrated the feasibility of targeting lymphoma lesions with somatostatin receptor binding agents, mainly with In-111-pentetreotide. In the present work another somatostatin analog, Tc-99m depreotide, is investigated.
Methods
One-hundred and six patients, 47 with Hodgkin’s (HL) and 59 with various types of non-Hodgkin’s lymphoma (NHL), were imaged with both Tc-99m depreotide and Ga-67 citrate. Planar whole-body and single photon emission tomography/low resolution computerized tomography (SPECT/CT) images were obtained. A total of 142 examinations were undertaken at different phases of the disease. Depreotide and gallium findings were compared visually and semi-quantitatively, with reference to the results of conventional work-up and the patients’ follow-up data.
Results
In most HL, intermediate- and low-grade B-cell, as well as in T-cell NHL, depreotide depicted more lesions than Ga-67 and/or exhibited higher tumor uptake. The opposite was true in aggressive B-cell NHL. However, there were notable exceptions in all lymphoma subtypes. During initial staging, 93.3% of affected lymph nodes above the diaphragm, 100% of inguinal nodes and all cases with splenic infiltration were detected by depreotide. On the basis of depreotide findings, 32% of patients with early-stage HL were upstaged. However, advanced HL and NHL cases were frequently downstaged, due to low sensitivity for abdominal lymph node (22.7%), liver (45.5%) and bone marrow involvement (36.4%). Post-therapy, depreotide detected 94.7% of cases with refractory disease or recurrence. Its overall specificity was moderate (57.1%). Rebound thymic hyperplasia, various inflammatory processes and sites of unspecific uptake were the commonest causes of false positive findings. The combination of depreotide and gallium enhanced sensitivity (100%), while various false positive results of either agent could be avoided.
Conclusion
Except perhaps for early-stage HL, Tc-99m depreotide as a stand-alone imaging modality has limited value for the initial staging of lymphomas. Post-therapy, however, depreotide scintigraphy seems useful in the evaluation of certain anatomic areas, particularly in non-aggressive lymphoma types. The combination with Ga-67 potentially enhances sensitivity and specificity. If fluorodeoxyglucose positron emission tomography is not available or in case of certain indolent lymphoma types, Tc-99m depreotide may have a role as an adjunct to conventional imaging procedures.
Similar content being viewed by others
References
Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S42–55.
Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S65–81.
Palumbo B, Sivolella S, Palumbo I, Liberati AM, Palumbo R. 67 Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:1011–7.
Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography. Clin Lymphoma. 2000;1:67–74.
Barrington SF, O’Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S117–27.
Ferone D, Semino C, Boschetti M, Cascini GL, Minuto F, Lastoria S. Initial staging of lymphoma with octreotide and other receptor imaging agents. Semin Nucl Med. 2005;35:176–85.
Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S. Indium- 111-Pentetreotide Uptake in Endocrine Tumors and Lymphoma. J Nucl Med. 1996;37:916–22.
Sarda L, Duet M, Zini JM, Berolatti B, Benelhadj S, Tobelem G, et al. Indium-111 pentetreotide scintigraphy in malignant lymphomas. Eur J Nucl Med. 1995;22:1105–9.
Lipp RW, Silly H, Ranner G, Dobnig H, Passath A, Leb G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med. 1995;36:13–8.
Ivancević V, Wörmann B, Nauck C, Sandrock D, Munz DL, Hiddemann W, et al. Somatostatin receptor scintigraphy in the staging of lymphomas. Leuk Lymphoma. 1997;26:107–14.
Lugtenburg PJ, Löwenberg B, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin’s lymphomas. J Nucl Med. 2001;42:222–9.
Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography. Horm Metab Res Suppl. 1993;27:56–8.
Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58:1850–9.
Raderer M, Valencak J, Pfeffel F, Drach J, Pangerl T, Kurtaran A, et al. Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type. J Natl Cancer Inst. 1999;91:716–8.
Dalm VASH, Hofland LJ, Mooy CM, Waaijers MA, van Koetsveld PM, Langerak AW, et al. Somatostatin receptors in malignant lymphomas: targets for radiotherapy? J Nucl Med. 2004;45:8–16.
Cholewinski W, Kowalczyk JR, Stefaniak B, Stefaniak J, Poniatowicz-Frasunek E, Tarkowska A. Diagnosis and staging of children’s lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide. Eur J Nucl Med Mol Imaging. 2004;31:820–4.
Bushnell DL, Menda Y, Madsen MT, Link BK, Kahn D, Truhlar SM, et al. 99mTc-depreotide tumour uptake in patients with non-Hodgkin’s lymphoma. Nucl Med Commun. 2004;25:839–43.
Montilla-Soler JL, Rexroad JT, Bridwell RS. Tc-99m depreotide scintigraphy of low-grade non-Hodgkin’s lymphoma. Clin Nucl Med. 2003;28:503–5.
Danielsson R, Bååth M, Kölbeck K-G, Klominek J, Svensson L. Accumulation of Tc-99m depreotide (NeoSpect) in axillary sweat glands. Clin Nucl Med. 2003;28:789–90.
Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy useful in stage I-II Hodgkin’s disease: more extended disease identified. Br J Haematol. 2001;112:936–44.
Lastoria S, Palmieri G, Muto P, Lombardi G. Functional imaging of thymic disorders. Ann Med. 1999;31(Suppl 2):63–9.
Reubi JC, Waser B, van Hagen M, Lamberts SWJ. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer. 1992;50:895–900.
Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175–83.
Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.
Raderer M, Traub T, Formanek M, Virgolini I, Osterreicher C, Fiebiger W, et al. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type. Br J Cancer. 2001;85:1462–6.
Landgren O, Tilly H. Epidemiology, pathology and treatment of non-follicular indolent lymphomas. Leuk Lymphoma. 2008;49(Suppl 1):35–42.
Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, et al. Marginal zone lymphomas: factors that affect the final outcome. Cancer 2010 [Epub ahead of print].
Acknowledgments
The authors acknowledge P. Barla, MD and A. Paschali, MD (residents in the department of Nuclear Medicine of the University Hospital of Patras), for their assistance in the performance of the scintigraphic studies, as well as in collecting, processing and organizing data.
Conflict of interest
The authors declare no financial conflict of interest in this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Apostolopoulos, D.J., Papandrianos, N.I., Symeonidis, A. et al. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. Ann Nucl Med 24, 639–647 (2010). https://doi.org/10.1007/s12149-010-0405-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-010-0405-7